DIHEXA in Clermont, Florida
Binding to hepatocyte growth factor (HGF) with extremely high affinity.
What Is Dihexa?
Dihexa, also known as PNB-0408, is a synthetic oligopeptide derived from angiotensin IV. It was specifically engineered to cross the blood-brain barrier and remain stable in the body, with excellent oral bioavailability.
Learn how Alliance approaches screening, sourcing, risks, and monitoring in our clinician-guided peptide therapy overview.
How It Works
Dihexa works by binding to hepatocyte growth factor (HGF) with extremely high affinity, amplifying HGF's activation of the c-Met receptor. This signaling pathway is one of the most powerful neurotrophic mechanisms in the brain. By enhancing c-Met activity, Dihexa promotes synaptogenesis (the formation of new neural connections), neurogenesis (the creation of new neurons), and improved neuronal survival. Studies have shown that Dihexa's synapse-building effects are several million times more potent than those of brain-derived neurotrophic factor (BDNF). It also reduces inflammation in the brain, downregulating harmful cytokines like IL-1β and TNF-α while increasing anti-inflammatory markers like IL-10. In animal models, it has reversed cognitive decline, improved memory and learning, and restored damaged neural pathways through PI3K/AKT signaling.
Benefits
- Preclinical models have demonstrated dramatic improvements in cognition, memory, and brain resilience following traumatic injury or neurodegenerative disease.
- Dihexa has shown the ability to restore lost synaptic density, enhance learning capacity, and improve long-term recall.
- Its half-life ranges from 9 to 12 days depending on administration, making it a long-acting therapeutic with sustained effects.
- What sets Dihexa apart is its blood-brain barrier penetration and its oral availability traits rare among neuropeptides. It has emerged as a promising compound in the field of neurorepair, neuroplasticity, and even early interventions for Alzheimer's and Parkinson's disease.
Safety Considerations
Although preclinical studies suggest Dihexa is well-tolerated and non-toxic in short-term use, the long-term safety profile is not fully known. Because it acts on the c-Met receptor, which is also involved in certain types of tumor growth, there is a theoretical concern about carcinogenicity with extended or unregulated use. No human clinical trials have been completed with Dihexa directly, though a related prodrug, fosgonimeton, is currently undergoing trials for neurodegenerative conditions. Until more clinical data are available, Dihexa should be used cautiously preferably cycled and only under guidance of a knowledgeable provider.
Molecule / Formula
C27H44N4O5
DIHEXA 10mg/5mL DOSING
- 10 units low dose
- 15 units moderate dose
- 20-25 units typical dose
Start low, acclimate, titrate up based on how you feel